BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Gene Solutions Partners with Topgen to Expand Advanced Cancer Genomics Across 1,300+ Chinese Hospitals

Gene Solutions has formalized a strategic collaboration with Zhejiang Shaoxing Topgen Biomedical Technology Co., Ltd., a CAP...

June 13, 2025 | News

Cytiva’s $1.6B Expansion Across 3 Continents to Boost Bioprocessing Supply

Faster delivery and productivity gains available thanks to expanded manufacturing capacity in chromatography resins, filtration, single-use bags and ...

June 12, 2025 | News

Kelun-Biotech’s TROP2 ADC and PD-L1 Combo Granted Breakthrough Therapy Designation in China for First-Line NSCLC

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab ti...

June 12, 2025 | News

Abbisko Therapeutics’ Pimicotinib NDA Accepted by China NMPA for Tenosynovial Giant Cell Tumor

Abbisko Therapeutics Co., Ltd. announced that the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) f...

June 11, 2025 | News

Sanyou Biopharmaceuticals and Medicovestor Forge Strategic Partnership to Advance First-in-Class Chemoimmunotherapy ADCs

Sanyou Biopharmaceuticals, a leading Shanghai-based high-tech biopharmaceutical company specializing in biologics R&D announced the signing ...

June 11, 2025 | News

ImmVira Doses First NMIBC Patient in Multi-Regional Phase II Trial of Novel Oncolytic Immunotherapy MVR-T3011

ImmVira, a global leading clinical-stage biotechnology company focused on the development of next-generation novel oncolytic immunotherapy for treatm...

June 11, 2025 | News

Neowise Licenses TCR Technology to BeOne Medicines for Off-the-Shelf iPSC-Based Cell Therapy Development

Neowise Biotechnology ("Neowise"), a pioneering company focused on the development of TCR-T cell therapies for solid tumors, announced today that it has en...

June 10, 2025 | News

VivaVision Receives Positive FDA Feedback on VVN461LD Phase 2 Trial for Ocular Inflammation

VivaVision Biotech (VivaVision), a late clinical-stage, privately-held biotech company focused on developing innovative ophthalmic drugs, announced today t...

June 10, 2025 | News

YolTech Therapeutics Receives FDA IND Clearance for In Vivo Base Editing Therapy YOLT-101

YolTech Therapeutics, a clinical-stage biotechnology company developing in vivo genome editing therapies, announced that the U.S. Food and Drug ...

June 09, 2025 | News

New Studies Presented at ERA 2025 Reinforce NEFECON®’s Early Intervention Value in IgA Nephropathy

Two new studies on NEFECON® demonstrate its treatment benefit in the "Treat Early" strategy for IgA nephropathy (IgAN), providing robust su...

June 09, 2025 | News

GenEditBio Doses First Patient in World's First In Vivo CRISPR Trial for TGFBI Corneal Dystrophy

GenEditBio Limited ("GenEditBio"), a clinical-stage biotechnology start-up company focusing on genome editing therapeutic solutions through the discovery o...

June 09, 2025 | News

QureBio Secures Nearly CNY 100 Million in Series C1 Funding Led by Efung Capital

Qure Biotechnology (Shanghai) Co., Ltd. (QureBio) announced that it has completed a Series C1 financing round. The financing raised nearly CNY 100 mil...

June 06, 2025 | News

ZEISS CLARUS® 700 Receives NMPA Approval in China, Enhancing Retinal Diagnostics

ZEISS Medical Technology announced that the CLARUS® 700 from ZEISS has received National Medical Products Administration (NMPA) approval in China,...

June 06, 2025 | News

Innovent and HUTCHMED’s Sintilimab-Fruquintinib Combo Accepted for NMPA Review in Advanced Renal Cell Carcinoma

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality me...

June 05, 2025 | News

Stay Connected